X

Drug Profile

Fermagate - OPKO Renal

Alternative Names: Alpharen; Macrosorb MD

Latest Information Update: 01 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator INEOS Silicas; OPKO Renal
Developer OPKO Renal
Class Carbonates; Iron compounds; Magnesium compounds; Small molecules
Mechanism of Action Phosphate binding modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Hyperphosphataemia

Most Recent Events

01 Aug 2019 Phase III development for Hyperphosphataemia is still ongoing in USA (OPKO Renal pipeline, August 2019)
11 Oct 2018 Chemical structure information added
26 May 2015 Fermagate is still in phase III trials for Hyperphosphataemia in the USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com